This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Apr;24(4):309-310.

doi: 10.1016/S1470-2045(23)00103-1.

Adding PD-1 inhibition to chemoradiotherapy for oesophageal cancer

Hanneke W M van Laarhoven¹, Peter S N van Rossum²

Affiliations

Affiliations

¹ Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, Netherlands. Electronic address: h.vanlaarhoven@amsterdamumc.nl.
² Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, Netherlands; Amsterdam UMC location Free University, Radiation Oncology, De Boelelaan 1118, Amsterdam, the Netherlands.

PMID: 36990605
DOI: 10.1016/S1470-2045(23)00103-1

Comment

Adding PD-1 inhibition to chemoradiotherapy for oesophageal cancer

Hanneke W M van Laarhoven et al. Lancet Oncol. 2023 Apr.

. 2023 Apr;24(4):309-310.

doi: 10.1016/S1470-2045(23)00103-1.

Authors

Hanneke W M van Laarhoven¹, Peter S N van Rossum²

Affiliations

¹ Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, Netherlands. Electronic address: h.vanlaarhoven@amsterdamumc.nl.
² Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, Netherlands; Amsterdam UMC location Free University, Radiation Oncology, De Boelelaan 1118, Amsterdam, the Netherlands.

PMID: 36990605
DOI: 10.1016/S1470-2045(23)00103-1

No abstract available

PubMed Disclaimer

Comment on

Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y, Liu M, Xi M. Zhu Y, et al. Lancet Oncol. 2023 Apr;24(4):371-382. doi: 10.1016/S1470-2045(23)00060-8. Lancet Oncol. 2023. PMID: 36990609 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information